These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27029727)

  • 121. PSA and beyond: alternative prostate cancer biomarkers.
    Saini S
    Cell Oncol (Dordr); 2016 Apr; 39(2):97-106. PubMed ID: 26790878
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Prostate cancer screening in Brazil: should it be done or not?
    Busato WF; Almeida GL
    Int Braz J Urol; 2016; 42(6):1069-1080. PubMed ID: 27619665
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Risk factors for metastatic prostate cancer: A sentinel event case series.
    Paller CJ; Cole AP; Partin AW; Carducci MA; Kanarek NF
    Prostate; 2017 May; 77(13):1366-1372. PubMed ID: 28786124
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis.
    Yin C; Luo C; Hu W; Ding X; Yuan C; Wang F
    Dis Markers; 2016; 2016():3825819. PubMed ID: 27766004
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis.
    Krishnan S; Kanthaje S; Punchappady DR; Mujeeburahiman M; Ratnacaram CK
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):951-967. PubMed ID: 35764700
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Beyond PSA testing for prostate cancer.
    Brooks D; Olver IN; Esterman AJ
    Med J Aust; 2018 Jun; 208(10):426-427. PubMed ID: 29848243
    [No Abstract]   [Full Text] [Related]  

  • 127. Assessing blood platelets as RNA biomarker source for prostate cancer.
    Hänze J; Jakubowski P; Heers H; Hegele A; Timmesfeld N; Hofmann R; Olbert PJ
    Biomarkers; 2016 Nov; 21(7):653-9. PubMed ID: 27121394
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Divergent Responses to Mammography and Prostate-Specific Antigen Recommendations.
    Martinez KA; Rothberg MB
    Am J Prev Med; 2017 Oct; 53(4):533-536. PubMed ID: 28318901
    [No Abstract]   [Full Text] [Related]  

  • 129. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.
    Carroll PR; Parsons JK; Andriole G; Bahnson RR; Barocas DA; Castle EP; Catalona WJ; Dahl DM; Davis JW; Epstein JI; Etzioni RB; Farrington T; Hemstreet GP; Kawachi MH; Lange PH; Loughlin KR; Lowrance W; Maroni P; Mohler J; Morgan TM; Nadler RB; Poch M; Scales C; Shaneyfelt TM; Smaldone MC; Sonn G; Sprenke P; Vickers AJ; Wake R; Shead DA; Freedman-Cass D
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1534-61. PubMed ID: 26656522
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation.
    Hoffman RM; Volk RJ; Wolf AMD
    Cancer; 2017 Oct; 123(20):3875-3878. PubMed ID: 28832967
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Defining the ideal tumor marker for prostate cancer.
    Montie JE; Meyers SE
    Urol Clin North Am; 1997 May; 24(2):247-52. PubMed ID: 9126220
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Beyond PSA: a need for additional markers for prostate cancer.
    Sartor O
    Clin Prostate Cancer; 2004 Dec; 3(3):135. PubMed ID: 15636677
    [No Abstract]   [Full Text] [Related]  

  • 133. Glycosylated biomarker sensors: advancements in prostate cancer diagnosis.
    Abd Rahman SF; Md Arshad MK; Gopinath SCB; Fathil MFM; Sarry F; Ibau C
    Chem Commun (Camb); 2021 Sep; 57(76):9640-9655. PubMed ID: 34473143
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Response.
    Stattin P; Carlsson S; Jonsson H
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269489
    [No Abstract]   [Full Text] [Related]  

  • 135. Re: prostate cancer mortality in areas with high and low prostate cancer incidence.
    Pinsky PF
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269488
    [No Abstract]   [Full Text] [Related]  

  • 136. Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk.
    Bentmar Holgersson M; Malm J; Lundberg Giwercman Y
    Eur Urol; 2017 Jun; 71(6):992-994. PubMed ID: 27993425
    [No Abstract]   [Full Text] [Related]  

  • 137. [New progress in precision diagnosis of prostate cancer].
    Ma Y; Chen YS
    Zhonghua Nan Ke Xue; 2016 Nov; 22(11):1030-1033. PubMed ID: 29281214
    [TBL] [Abstract][Full Text] [Related]  

  • 138. [2014 Annual Meeting of the American Urological Association: early screening and molecular markers of prostate cancer].
    Tao T; Guan H; Chen M
    Zhonghua Nan Ke Xue; 2015 Jun; 21(6):555-60. PubMed ID: 26242049
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Moving toward a more rational, evidence-based approach to PSA screening, diagnosis, and treatment of prostate cancer.
    Filson CP
    Cancer; 2018 Jul; 124(13):2684-2686. PubMed ID: 29781113
    [No Abstract]   [Full Text] [Related]  

  • 140. Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.
    Yang B; Liao GQ; Wen XF; Chen WH; Cheng S; Stolzenburg JU; Ganzer R; Neuhaus J
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):921-933. PubMed ID: 29119730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.